Luiz Carlos da Silva Pinheiro

Prof. Dr. Luiz Carlos da Silva Pinheiro

DCIEN, Rio de Janeiro State University, Rio de Janeiro, Brazil
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2013 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
MFMaria De Lourdes G Ferreira
Maria De Lourdes G Ferreira
Luiz Carlos da Silva PinheiroLuiz Carlos da Silva Pinheiro
Luiz Carlos da Silva Pinheiro
Osvaldo Andrade Santos-FilhoOsvaldo Andrade Santos-Filho
Osvaldo Andrade Santos-Filho
MPMarta D S Pecanha
Marta D S Pecanha
CSCarolina Q Sacramento
Carolina Q Sacramento
NBNubia Boechat
Nubia Boechat

1 August 2006 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
ABAlice Maria Rolim Bernardino
Alice Maria Rolim Bernardino
Luiz Carlos da Silva PinheiroLuiz Carlos da Silva Pinheiro
Luiz Carlos da Silva Pinheiro
CRCarlos Rangel Rodrigues
Carlos Rangel Rodrigues
NLNatália Izabel Loureiro
Natália Izabel Loureiro
HCHelena Carla Castro
Helena Carla Castro
MVMarcos André Vannier-Santos
Marcos André Vannier-Santos

5 June 2014 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
PDF file
NBNubia Boechat
Nubia Boechat
MFMaria De Lourdes G. Ferreira
Maria De Lourdes G. Ferreira
Luiz Carlos da Silva PinheiroLuiz Carlos da Silva Pinheiro
Luiz Carlos da Silva Pinheiro
AJAntônio M. L. Jesus
Antônio M. L. Jesus
MLMilene M. M. Leite
Milene M. M. Leite
AKAntoniana U. Krettli
Antoniana U. Krettli

1 January 2018 in Anais da Academia Brasileira de Ciências
Verified
Journal Article
Open access
PDF file
Luiz Carlos da Silva PinheiroLuiz Carlos da Silva Pinheiro
Luiz Carlos da Silva Pinheiro
LFLívia M. Feitosa
Lívia M. Feitosa
FSFlávia F. DA Silveira
Flávia F. DA Silveira
NBNubia Boechat
Nubia Boechat
According to the World Health Organization, malaria remains one of the biggest public health problems in the world. The development of resistance is a current concern, mainly because the number of safe drugs for this disease is limited. Artemisinin-based combination therapy is recommended by the World Health Organization to prevent or delay the onset of resistance. Thus, the need to obtain new drugs makes artemisinin the most widely used scaffold to obtain synthetic compounds. This review describes the drugs based on artemisinin and its derivatives, including hybrid derivatives and dimers, trimers and tetramers that contain an endoperoxide bridge. This class of compounds is of extreme importance for the discovery of new drugs to treat malaria.

13 November 2019 in Molecules
Verified
Journal Article
Open access
PDF file
Luiz Carlos da Silva PinheiroLuiz Carlos da Silva Pinheiro
Luiz Carlos da Silva Pinheiro
LFLívia M. Feitosa
Lívia M. Feitosa
MGMARILIA Oliva GANDI
MARILIA Oliva GANDI
FSFlávia F. Silveira
Flávia F. Silveira
NBNubia Boechat
Nubia Boechat
Based on medicinal chemistry tools, new compounds for malaria treatment were designed. The scaffolds of the drugs used to treat malaria, such as chloroquine, primaquine, amodiaquine, mefloquine and sulfadoxine, were used as inspiration. We demonstrated the importance of quinoline and non-quinoline derivatives in vitro with activity against the W2 chloroquine-resistant (CQR) Plasmodium falciparum clone strain and in vivo against Plasmodium berghei-infected mouse model. Among the quinoline derivatives, new hybrids between chloroquine and sulfadoxine were designed, which gave rise to an important prototype that was more active than both chloroquine and sulfadoxine. Hybrids between chloroquine–atorvastatin and primaquine–atorvastatin were also synthesized and shown to be more potent than the parent drugs alone. Additionally, among the quinoline derivatives, new mefloquine derivatives were synthesized. Among the non-quinoline derivatives, we obtained excellent results with the triazolopyrimidine nucleus, which gave us prototype I that inspired the synthesis of new heterocycles. The pyrazolopyrimidine derivatives stood out as non-quinoline derivatives that are potent inhibitors of the P. falciparum dihydroorotate dehydrogenase (PfDHODH) enzyme. We also examined the pyrazolopyridine and pyrazolopyrimidine nuclei.

13 December 2007 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
ABAlice Maria Rolim Bernardino
Alice Maria Rolim Bernardino
AAAlexandre Reis de Azevedo
Alexandre Reis de Azevedo
Luiz Carlos da Silva PinheiroLuiz Carlos da Silva Pinheiro
Luiz Carlos da Silva Pinheiro
JBJúlio Cesar Borges
Júlio Cesar Borges
VCVinícius Lucio Carvalho
Vinícius Lucio Carvalho
IFIzabel Christina Palmer Paixão de Frugulhetti
Izabel Christina Palmer Paixão de Frugulhetti